Literature DB >> 3392895

Erythrocytapheresis. A method for rapid extracorporeal elimination of erythrocytes. Results in 65 patients.

W G Zoller1, H Kellner, F A Spengel.   

Abstract

We report on the progress of a new modified method of phlebotomy, erythrocytapheresis, as a means of fast therapeutic removal of erythrocytes from the circulation. We performed erythrocytapheresis in 65 patients. In 18 patients with central venous thrombosis of the eye, the beneficial effect of this procedure proved superior to the traditional approach. In 29 patients with primary or secondary polycythemia, hemoglobin, hematocrit, and blood viscosity could be lowered drastically for up to 11 months by a single erythrocytapheresis. We performed erythrocytapheresis in an effort to deplete the iron stores in patients with hemochromatosis (14 cases) and in patients with porphyria cutanea tarda (4 cases). Several consecutive erythrocytaphereses were necessary, however, to even slightly lower the amounts of stored iron as measured by serum iron, iron-binding capacity, and serum ferritin in these patients. The intervals between treatment were 2 to 11 months, thus much longer than the intervals between blood-lettings. We did not observe any adverse side effects. There was no significant influence on the clotting system, and no reactive thrombocytosis as described after phlebotomies.

Entities:  

Mesh:

Year:  1988        PMID: 3392895     DOI: 10.1007/bf01737944

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  23 in total

1.  A micromethod of euglobulin fibrinolysis in plasma of human subjects and small laboratory animals.

Authors:  A L COPLEY; S NIEWIAROWSKI; J MARECHAL
Journal:  J Lab Clin Med       Date:  1959-03

2.  [Pathology of arterial and venous occlusive diseases of the retina (author's transl)].

Authors:  B Daicker
Journal:  Klin Monbl Augenheilkd       Date:  1977-02       Impact factor: 0.700

3.  [The effect of bloodletting on the excretion of porphyrius and clelta aminolevulinic acid as well as the clinical picture of porphyria cutanea tarda].

Authors:  I Broese; A Mattheus
Journal:  Dermatol Monatsschr       Date:  1977-02

4.  [Results and indications for drug therapy in arterial and venous vascular occlusions of the retina due to erythrosclerosis].

Authors:  G Gallasch
Journal:  Fortschr Ophthalmol       Date:  1985

5.  Heparin cofactor activity measured with an amidolytic method.

Authors:  O R Odegard; M Lie; U Abildgaard
Journal:  Thromb Res       Date:  1975-04       Impact factor: 3.944

6.  [Porphyria cutanea tarda].

Authors:  G Goerz
Journal:  Fortschr Med       Date:  1979-09-27

7.  Viscosity and retinal vein thrombosis.

Authors:  C P Ring; T C Pearson; M D Sanders; G Wetherley-Mein
Journal:  Br J Ophthalmol       Date:  1976-06       Impact factor: 4.638

8.  [Hemorrhagic glaucoma (author's transl)].

Authors:  P Drobec
Journal:  Klin Monbl Augenheilkd       Date:  1982-02       Impact factor: 0.700

9.  Long-term follow-up of occlusion of the central retinal vein in young adults.

Authors:  I A Priluck; D M Robertson; R W Hollenhorst
Journal:  Am J Ophthalmol       Date:  1980-08       Impact factor: 5.258

10.  Erythrapheresis in patients with polycythaemia secondary to hypoxic lung disease.

Authors:  J A Wedzicha; R M Rudd; M C Apps; F E Cotter; A C Newland; D W Empey
Journal:  Br Med J (Clin Res Ed)       Date:  1983-02-12
View more
  3 in total

1.  Treatment of polycythemia vera by isovolemic large-volume erythrocytapheresis.

Authors:  U Kaboth; K W Rumpf; T Lipp; J Bigge; M Nauck; J H Beyer; W Seyde; W Kaboth
Journal:  Klin Wochenschr       Date:  1990-01-04

2.  Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis.

Authors:  Tatjana Sundic; Tor Hervig; Signe Hannisdal; Jörg Assmus; Rune J Ulvik; Richard W Olaussen; Sigbjørn Berentsen
Journal:  Blood Transfus       Date:  2013-10-23       Impact factor: 3.443

3.  A predictive model for estimating the number of erythrocytapheresis or phlebotomy treatments for patients with naïve hereditary hemochromatosis.

Authors:  Eva Rombout-Sestrienkova; Bjorn Winkens; Marian van Kraaij; Cees Th B M van Deursen; Mirian C H Janssen; Alexander M J Rennings; Dorothea Evers; Jean-Louis Kerkhoffs; Ad Masclee; Ger H Koek
Journal:  J Clin Apher       Date:  2020-12-24       Impact factor: 2.821

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.